New drug toxicities in the onco-nephrology world

Kidney International

Volumn 87, Issue 5, 2015, Pages 909-917

  Perazella, Mark A ^a   Izzedine, Hassan ^b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Monceau Park International Clinic   (France)

Author keywords

acute kidney injury; chemotherapy; chronic kidney disease; onco nephrology

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; BRIVANIB; CARBOPLATIN; CARFILZOMIB; CEDIRANIB; CISPLATIN; CLOFARABINE; CORTICOSTEROID; CRIZOTINIB; DEXAMETHASONE; GATAPARSEN; GEMCITABINE; IPILIMUMAB; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PAZOPANIB; PEMETREXED; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAPRIL; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; ZOLEDRONIC ACID; ADENINE NUCLEOTIDE; ANTIANDROGEN; ARABINONUCLEOSIDE; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; BREAST CANCER; CANCER PATIENT; CANCER RESISTANCE; CHRONIC KIDNEY DISEASE; COLITIS; DERMATITIS; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL TUMOR; GLOMERULONEPHRITIS; HEPATITIS; HUMAN; HYPERTENSION; HYPOPHYSITIS; IMMUNE COMPLEX NEPHRITIS; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; KIDNEY INJURY; LOW DRUG DOSE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METASTATIC MELANOMA; MINIMAL CHANGE GLOMERULONEPHRITIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROLOGIST; NEPHROTIC SYNDROME; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REPEATED DRUG DOSE; REVIEW; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROIDITIS; CHEMICALLY INDUCED; KIDNEY DISEASE;

ADENINE NUCLEOTIDES; ANDROGEN ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; HUMANS; KIDNEY DISEASES; OLIGOPEPTIDES; PEMETREXED; PYRAZOLES; PYRIDINES;

EID: 84929132084     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.30     Document Type: Review

References (71)

1. Perazella MA, Moeckel G. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology and prevention/therapy. Sem Nephrol 2010; 30: 570-581.
2. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 2012; 7: 1713-1721.
3. Abudayyeh AA, Lahoti A, Salahudeen AK. Onconephrology: the need and the emergence of a subspecialty in nephrology. Kidney Int 2014; 85: 1002-1004.
4. Soria JC, Massard C, Izzedine H. From theoretical synergy to clinical supraadditive toxicity. J Clin Oncol 2009; 27: 1359-1361.
5. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807-815.
6. Izzedine H, Massard C, Spano JP et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46: 439-448.
7. den Deurwaarder ES, Desar IM, Steenbergen EJ et al. Kidney injury during VEGF inhibitor therapy. Neth J Med 2012; 70: 267-271.
8. Vigneau C, Lorcy N, Dolley-Hitze T et al. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study. Nephrol Dial Transplant 2014; 29: 325-332.
9. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
10. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and metaanalysis. Acta Oncol 2009; 48: 9-17.
11. Langenberg MH, van Herpen CM, De Bono J et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 2009; 27: 6152-6159.
12. Yamamoto N, Tamura T, Yamada K et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2009; 64: 1165-1172.
13. Izzedine H, Escudier B, Lhomme L et al. Anti-VEGF associated kidney diseases: a 8-year monocentric observational study. Medicine 2014; 93: 333-339.
14. Izzedine H, Isnard-Bagnis C, Launay-Vacher V et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006; 21: 3038-3045.
15. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007; 18: 1117.
16. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763-773.
17. Mir O, Ropert S, Alexandre J et al. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 2009; 20: 967-970.
18. Izzedine H, Mangier M, Ory V et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 2014; 85: 457-470.
19. Bollée G, Patey N, Cazajous G et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009; 24: 682-685.
20. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244.
21. Shahinian VB, Kuo YF, Freeman JL et al. Increasing use of gonadotropinreleasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-1624.
22. Lapi F, Azoulay L, Niazi MT et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 2013; 310: 289-296.
23. Gandaglia G, Sun M, Hu JC et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol 2014; 66: 1125-1132.
24. Brosnan EM, Weickhardt AJ, Lu X et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive nonsmall cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2014; 120: 664-674.
25. Gastaud L, Ambrosetti D, Otto J et al. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. Lung Cancer 2013; 82: 362-364.
26. Martorell PM, Alvaro MH, Salguero MAS et al. Crizitonib and renal insufficiency: a case report and review of the literature. Lung Cancer 2014; 84: 310-313.
27. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019.
28. Christensen JG, Zou HY, Arango ME et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6: 3314-3322.
29. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67: 4408-4417.
30. Johnson TR, Tan W, Goulet L et al. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica 2014; 18: 1-15.
31. Kantarjian H, Gandhi V, Cortes J et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379-2386.
32. Nabhan C, Davis N, Bitran JD et al. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximabrefractory patients. Cancer 2011; 117: 1490-1497.
33. Faderl S, Ravandi F, Huang X et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and highrisk myelodysplastic syndrome. Blood 2008; 112: 1638-1645.
34. Gandhi V, Plunkett W, Bonate PL et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 2006; 12: 4011-4017.
35. Kintzel PE, Visser JA, Campbell AD. Clofarabine-associated acute kidney injury and proteinuria. Pharmacotherapy 2011; 31: 923.
36. Faderl S, Ravandi F, Huang X et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012; 118: 4471-4477.
37. Farag SS, Wood LL, Schwartz JE et al. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 2011; 25: 599-605.
38. Kirschbaum MH, Stein AS, Popplewell L et al. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant 2012; 18: 432-440.
39. Claxton D, Erba HP, Faderl S et al. CLASSIC II investigators. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma 2012; 53: 435-440.
40. Burnett AK, Russell NH, Kell J et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28: 2389-2395.
41. Petri CR, O'Donnell PH, Cao H et al. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma 2014; 27: 1-8.
42. Jhaveri KD, Chidella S, Allen SL et al. Clofarabine-induced kidney toxicity. J Oncol Pharm Pract 2013; 20: 305-308.
43. Hughes A, Calvert P, Azzabi A et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20: 3533-3544.
44. Kurata T, Iwamoto T, Kawahara Y et al. Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3. Drug Metab Pharmacokinet 2014; 29: 148-153.
45. Michels J, Spano JP, Brocheriou I et al. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol 2009; 2: 53-56.
46. Vootukuru V, Liew YP, Nally JV. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with nonsmall cell lung cancer. Med Oncol 2006; 23: 419-422.
47. Stavroulopoulos A, Nakopoulou L, Xydakis AM et al. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 2010; 32: 1000-1004.
48. Chauvet S, Courbebaisse M, Ronco P et al. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. Clin Nephrol 2014; 82: 402-406.
49. Castro M. Thymidine rescue: An antidote for pemetrexed related toxicity in the setting of acute renal failure. J Clin Oncol 2003; 21: 4066-4069.
50. Glezerman IG, Pietanza MC, Miller V et al. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis 2011; 58: 817-820.
51. Rinaldi DA, Kuhn JG, Burris HA et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999; 44: 372-380.
52. Takimoto CH, Hammond-Thelin LA, Latz JE et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007; 13: 2675-2683.
53. van den Bogaert DP, Pouw EM, van Wijhe G et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006; 1: 25-30.
54. Llombart-Cussac A, Martin M, Harbeck N et al. A randomized, doubleblind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res 2007; 13: 3652-3659.
55. Hazarika M, White RM, Johnson JR et al. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004; 9: 482-488.
56. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1698-1704.
57. Latz JE, Chaudhary A, Ghosh A et al. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006; 57: 401-411.
58. Mita AC, Sweeney CJ, Baker SD et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006; 24: 552-562.
59. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Alimta 2004; available from http://www.accessdata.fda.gov/ drugsatfda-docs/label/2004/021677lbl.pdf.
60. Yang K, Yang J, Kirk C et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 2013; 41: 230-237.
61. Jhaveri KD, Chidella S, Varghese J et al. Carfilzomib-related acute kidney injury. Clin Adv Hematol Oncol 2013; 11: 604-605.
62. Siegel D, Martin T, Nooka A et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98: 1753-1761.
63. Harvey R. Abstract and poster presented at the Lymphoma and Myeloma Congress, 25-27 October 2012; New York, NY, USA.
64. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
65. Friedline RH, Brown DS, Nguyen H et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009; 206: 421-434.
66. Chmiel KD, Suan D, Liddle C et al. Resolution of severe ipilimumabinduced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011; 29: e237-e240.
67. Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 2011; 5: 489-495.
68. Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e537-e545.
69. Izzedine H, Gueutin V, Gharbi C et al. Kidney injuries related to ipilimumab. Invest New Drugs 2014; 32: 169-173.
70. Spanou Z, Keller M, Britschgi M et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 2006; 17: 2919-2927.
71. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361: 211-212.